✦ LIBER ✦

Phase II study of lonidamine in metastatic breast cancer

✍ Scribed by Pronzato, P; Amoroso, D; Bertelli, G; Conte, PF; Cusimano, MP; Ciottoli, GB; Gulisano, M; Lionetto, R; Rosso, R

Book ID: 109836309
Publisher: Nature Publishing Group
Year: 1989
Tongue: English
Weight: 540 KB
Volume: 59
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1989.51

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of lonidamine in metastat

Phase II study of lonidamine in metastatic prostatic carcinoma

✍ David J. Stewart; Susan E. Aitken; Allen H. Irvine; David E. Moors; Norman G. Fu 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 132 KB

Phase II study of deoxyspergualin in met

Phase II study of deoxyspergualin in metastatic breast cancer

✍ Kapil Dhingra; Vicente Valero; Lia Gutierrez; Richard Theriault; Daniel Booser; 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 553 KB

Lonidamine plus epirubicin and cyclophos

Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study

✍ G. Gardin; C. Barone; O. Nascimben; G. Ianniello; F. Sturba; A. Contu; P. Pronza 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 255 KB

Phase II study of semisynthetic paclitax

Phase II study of semisynthetic paclitaxel in metastatic breast cancer

✍ C. Hudis; L. Riccio; F. Holmes; A. Seidman; J. Baselga; V. Currie; D. Fennelly; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 609 KB

Phase II study of deoxydoxorubicin in pr

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

✍ Sitvana Martino; Bohumil A. Samal; Bruce Redman; Lawrence Flaherty; Michael Krau 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 425 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi